CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2 enrolled
Drug / intervention
Omegavendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03662282
NCT03662282Phase 3Completed
CompareCT.gov

Omegaven as Alternative Parenteral Fat Nutrition

University of South Florida·interventional·Posted Sep 7, 2018·Updated Jul 22, 2020

In Brief

A Phase 3 clinical trial evaluating Omegaven for Cholestasis and Cholestasis of Parenteral Nutrition. Completed, enrolled 2 participants across 1 site.

Detailed Summary

To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholestasis, Cholestasis of Parenteral Nutrition
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 7, 2018
Enrollment StartOct 23, 2018
Primary CompletionJan 7, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.8 years ago

Interventions

Omegavendrug

Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury